Qube Research & Technologies Ltd acquired a new stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 32,800 shares of the company’s stock, valued at approximately $581,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Hudock Capital Group LLC bought a new position in shares of Takeda Pharmaceutical in the 1st quarter worth about $26,000. Steward Partners Investment Advisory LLC bought a new position in shares of Takeda Pharmaceutical in the 2nd quarter worth about $31,000. Coastal Investment Advisors Inc. lifted its position in shares of Takeda Pharmaceutical by 59.8% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after buying an additional 643 shares during the last quarter. Parallel Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the 1st quarter worth about $33,000. Finally, Stuart Chaussee & Associates Inc. bought a new position in shares of Takeda Pharmaceutical in the 1st quarter worth about $33,000. Hedge funds and other institutional investors own 10.83% of the company’s stock.

TAK has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. ValuEngine downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, Daiwa Capital Markets downgraded shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research report on Thursday.

NYSE:TAK traded up $0.08 during mid-day trading on Monday, hitting $16.80. The stock had a trading volume of 506,379 shares, compared to its average volume of 1,493,222. The stock has a market capitalization of $26.34 billion, a PE ratio of 32.94 and a beta of 0.69. The stock’s 50 day moving average is $17.52. Takeda Pharmaceutical Co Ltd has a 52 week low of $15.50 and a 52 week high of $21.95. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 1.01.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Recommended Story: What is Compound Annual Growth Rate (CAGR)?

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.